This story was originally posted on April 1.
PGXL Laboratories will offer warfarin and CYP450 2C19 testing on AutoGenomics' Infiniti system, the companies announced this week.
PGXL, a Louisville, Ky.-based pharmacogenomics services provider, also plans to introduce other AutoGenomics assays, such as its KRAS-BRAF test, in the future.
PGXL offers pharmacogenetic testing and interpretive services in its US Clinical Laboratory Improvement Acts-compliant facility. It also performs contract research for manufacturers of pharmaceuticals and medical equipment.
AutoGenomics' Infiniti platform makes use of the Vista, Calif.-based firm's BioFilmChip microarray technology, which consists of multiple layers of hydrogel matrices about 10 µm thick on a polyester solid support. AutoGenomics' warfarin and CYP450 2C19+ tests, in addition to several others, have been cleared by the US Food and Drug Administration for clinical use. The company is discussing additional submissions with the agency, including its KRAS and BRAF assay (BAN 1/25/2011).
Mark Linder, executive vice president of operations at PGXL, cited AutoGenomics' "comprehensive menu of molecular applications in the pharmacogenetics arena" as a reason why the testing company adopted the Infiniti platform.
Ram Vairavan, senior vice president of AutoGenomics, said that its array technology "allows us to rapidly develop new test applications to meet the evolving needs in companion diagnostic testing and enable PGXL Labs to expand the array of personalized medicine tests."
Further details of the deal were not discussed.